logo-loader
viewVerastem Oncology

Verastem Oncology shares take a nose dive after launching stock offering

Verastem stock slumped 12% to US$4.62 after the group priced 7,777,778 shares of its common stock at US$4.50

Cancer headline in a newspaper
The offering is set to raise US$35mln

Shares of Verastem Oncology (NASDAQ:VSTM)  took a nose dive after the cancer drug specialist revealed that it is diluting its shares by launching another share offering.

Verastem stock slumped 12% to US$4.62 after the group priced 7,777,778 shares of its common stock at US$4.50. This offering is expected to raise US$35mln on a gross basis.

Verastem, which is based in Boston, has also granted the underwriter a thirty-day window to purchase up to an additional 1,166,666 shares of its common stock, which are worth about US$5.25mln.

Cantor Fitzerald will act as the sole book-runner for the offering, which is expected to close on May 18, subject to closing conditions.

Quick facts: Verastem Oncology

Price: 0.95 USD

NASDAQ:VSTM
Market: NASDAQ
Market Cap: $70.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Weekend Unlimited expects to grow their business "organically"

Weekend Unlimited (CSE: POT) CEO  Chris Backus sat down with Steve Darling from Proactive Vancouver to bring news the company is going full steam ahead with their hemp asset Northern Lights. Backus talks about what is happening to ensure they become leaders in the sector. Backus also...

55 minutes ago

2 min read